Coherus Oncology, Inc.

For the period ended Dec 31, 2025. Filed Mar 9, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 9, 2026

CHRS$0.82+6.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations


· · · · Year Ended December 31,
· · · · 2025 · · 2024
Net revenue	$42,172	$26,389
Costs and expenses:
Cost of goods sold	13,814	8,727
Research and development	108,888	91,833
Selling, general and administrative	100,604	125,482
Total costs and expenses	223,306	226,042
Loss from operations	(181,134)	(199,653)
Interest expense	(9,001)	(10,734)
Loss on debt extinguishment	—	(12,630)
Other income (expense), net	7,011	7,623
Loss from continuing operations before income taxes	(183,124)	(215,394)
Income tax provision	—	—
Net loss from continuing operations	(183,124)	(215,394)
Net income from discontinued operations, net of tax (Note 6)	351,148	243,901
Net income	$168,024	$28,507

Net income (loss) per share:
Net loss from continuing operations - basic and diluted	$(1.56)	$(1.88)
Net income from discontinued operations - basic and diluted	$3.00	$2.13
Net income per share - basic and diluted	$1.43	$0.25

Weighted-average number of shares used in computing net income (loss) per share:
Basic and diluted	117,143,457	114,553,537

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.